JP2003521508A5 - - Google Patents

Download PDF

Info

Publication number
JP2003521508A5
JP2003521508A5 JP2001556240A JP2001556240A JP2003521508A5 JP 2003521508 A5 JP2003521508 A5 JP 2003521508A5 JP 2001556240 A JP2001556240 A JP 2001556240A JP 2001556240 A JP2001556240 A JP 2001556240A JP 2003521508 A5 JP2003521508 A5 JP 2003521508A5
Authority
JP
Japan
Prior art keywords
active ingredient
liposome
compound
solvent
dehydrated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001556240A
Other languages
English (en)
Other versions
JP4786105B2 (ja
JP2003521508A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2001/000391 external-priority patent/WO2001056548A2/en
Publication of JP2003521508A publication Critical patent/JP2003521508A/ja
Publication of JP2003521508A5 publication Critical patent/JP2003521508A5/ja
Application granted granted Critical
Publication of JP4786105B2 publication Critical patent/JP4786105B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項1】 親油性活性成分を含有するリポソームを形成するための方法であって、
溶液を形成するため溶媒に前記活性成分を溶解させて懸濁液を作製する工程、
この溶液へ該活性成分を沈殿させる沈殿剤を添加する工程、
上澄みから沈殿物を分離する工程、
粒子状形態の該活性成分の懸濁液を作製するために該沈殿物を非溶媒に再懸濁させる工程、
リポソーム形成化合物から形成された予め形成された空リポソームの水性懸濁液を、リポソーム形成化合物:活性成分の重量比が(10未満):1の範囲の量で、前記活性成分の懸濁液と混合する工程、
糖:リポソーム形成化合物の重量比が(5を超える):1の範囲の量で、リポソームの水性懸濁液に糖を溶解させる工程、
空リポソーム、粒子状活性成分および溶解された糖を含有する水性懸濁液を脱水する工程、ならびに
該脱水プロダクトを水性再水和媒体に再水和させて、脱水/再水和小胞を形成する工程、
を含む、方法。
【請求項2】 前記再水和媒体が水からなる、請求項1に記載の方法。
【請求項】 前記溶媒が、アルコール、エーテルまたはグリコールエーテルであり、そして前記沈殿剤および非溶媒が両方とも水である、請求項に記載の方法。
【請求項】 前記溶媒が、エタノールおよび低分子量ポリエチレングリコールから選択される、請求項に記載の方法。
【請求項】 前記脱水が、噴霧乾燥または凍結乾燥によって行われる、請求項1〜4のいずれかに記載の方法。
【請求項】 前記糖が、単糖類または二糖類である、請求項1〜5のいずれかに記載の方法。
【請求項7】 前記糖が、スクロースである、請求項6に記載の方法。
【請求項】 前記リポソーム形成化合物、非イオン性または双性イオン性化合物を少なくとも1つ含む、請求項1〜7のいずれかに記載の方法。
【請求項9】 前記リポソーム形成化合物が、ホスファチジルコリンを含む、請求項8に記載の方法。
【請求項10】 前記リポソーム形成化合物が、さらに、アニオン性化合物を含む、請求項9に記載の方法。
【請求項11 リポソーム形成化合物活性成分重量比が7.5:(少なくとも1)である、請求項1〜10のいずれかに記載の方法。
【請求項12】 前記水性懸濁液中のリポソームが、100nm未満の平均直径を有する、請求項1〜11のいずれかに記載の方法。
【請求項13】 前記脱水/再水和小胞が、前記水性懸濁液中のリポソームの平均粒度よりも大きな平均粒度を有する、請求項12に記載の方法。
【請求項14】 前記脱水/再水和小胞が1000nm未満の平均直径を有する、請求項13に記載の方法。
【請求項15】 前記脱水/再水和小胞が500nm未満の平均直径を有する、請求項14に記載の方法。
【請求項16】 前記活性成分が、タキサン(taxane)である、請求項1〜15のいずれかに記載の方法。
【請求項17】 前記活性成分が、パクリタキセル(paclitaxel)である、請求項16に記載の方法。
JP2001556240A 2000-02-04 2001-01-31 リポソーム Expired - Fee Related JP4786105B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00300904.0 2000-02-04
EP00300904 2000-02-04
PCT/GB2001/000391 WO2001056548A2 (en) 2000-02-04 2001-01-31 Liposomes composition produced by a dehydration-rehydration process

Publications (3)

Publication Number Publication Date
JP2003521508A JP2003521508A (ja) 2003-07-15
JP2003521508A5 true JP2003521508A5 (ja) 2009-05-14
JP4786105B2 JP4786105B2 (ja) 2011-10-05

Family

ID=8172682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001556240A Expired - Fee Related JP4786105B2 (ja) 2000-02-04 2001-01-31 リポソーム

Country Status (8)

Country Link
US (1) US7025988B2 (ja)
EP (1) EP1259225B1 (ja)
JP (1) JP4786105B2 (ja)
AT (1) ATE341310T1 (ja)
AU (1) AU2869901A (ja)
DE (1) DE60123583T2 (ja)
ES (1) ES2272496T3 (ja)
WO (1) WO2001056548A2 (ja)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030059375A1 (en) * 2001-08-20 2003-03-27 Transave, Inc. Method for treating lung cancers
RU2341296C2 (ru) 2002-05-24 2008-12-20 Энджиотек Интернэшнл Аг Композиции и способы покрытия медицинских имплантатов
DE60329497D1 (de) 2002-06-26 2009-11-12 Medigene Ag Herstellung einer kationisch liposomalen zubereitung, einen lipophilen wirkstoff enthaltend
CN100340289C (zh) 2002-07-05 2007-10-03 利普生技术有限公司 增强核酸接种免疫应答的方法
BRPI0313191A2 (pt) * 2002-08-02 2016-11-08 Transave Inc composição e processo para produzir um agregado de platina e formulação farmacêutica
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
US20050255164A1 (en) * 2002-08-15 2005-11-17 Yunging Liu Solid nano pharmaceutical formulation and preparation method thereof
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
EP1613284A2 (en) * 2003-02-11 2006-01-11 Neopharm, Inc. Manufacturing process for liposomal preparations
WO2005002546A1 (en) * 2003-06-27 2005-01-13 Smithkline Beecham Corporation Stabilized topotecan liposomal composition and methods
US20050048109A1 (en) * 2003-08-26 2005-03-03 Ceramoptec Industries, Inc. Non-polar photosensitizer formulations for photodynamic therapy
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
EP1729786A4 (en) * 2004-03-18 2008-03-26 Transave Inc ADMINISTRATION OF CISPLATIN BY INHALATION
ES2967961T3 (es) 2004-05-03 2024-05-06 Ipsen Biopharm Ltd Liposomas útiles en la administración de fármacos
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
CN101001633A (zh) * 2004-05-21 2007-07-18 特兰萨夫公司 肺病和肺病前期病症的治疗
US7608579B2 (en) * 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US20050281798A1 (en) * 2004-06-16 2005-12-22 Glen Gong Targeting sites of damaged lung tissue using composition
US7553810B2 (en) * 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
US20050281739A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue using compositions
US7468350B2 (en) 2004-06-16 2008-12-23 Pneumrx, Inc. Glue composition for lung volume reduction
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US7766938B2 (en) 2004-07-08 2010-08-03 Pneumrx, Inc. Pleural effusion treatment device, method and material
KR20070089693A (ko) * 2004-11-08 2007-08-31 트랜세이브, 인코포레이티드 지질-기재 플래티넘 화합물 제형을 복막내 투여하여 암을치료하는 방법
EP1906924B1 (en) 2005-06-06 2018-05-02 Waseda University Bone marrow-directing drug delivery materials and their applications
TWI291237B (en) * 2005-10-07 2007-12-11 Integrated Digital Technologie Photo detector array
WO2007056264A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056236A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US8226975B2 (en) 2005-12-08 2012-07-24 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
JP5600432B2 (ja) * 2006-04-06 2014-10-01 インスメッド, インコーポレイテッド コアセルベート化誘導リポソーム被包法及びその調合物
JP2010504410A (ja) * 2006-09-20 2010-02-12 ヌームアールエックス, インコーポレイテッド 組織接着剤組成物およびその方法
WO2008137717A1 (en) * 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9445975B2 (en) 2008-10-03 2016-09-20 Access Business Group International, Llc Composition and method for preparing stable unilamellar liposomal suspension
EP2349309A4 (en) * 2008-11-20 2014-01-08 Teikoku Pharma Usa Inc FORMULATIONS OF PYRAZOLE DERIVATIVES
US20110070294A1 (en) * 2009-09-23 2011-03-24 Javeri Indu Methods for the Administration of Drugs Using Liposomes
EP2480209A1 (en) * 2009-09-23 2012-08-01 Indu Javeri Methods for the preparation of liposomes comprising docetaxel
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
EP2394640A1 (en) 2010-05-21 2011-12-14 MediGene AG Improved liposomal formulations of lipophilic compounds
EP4005576B1 (en) 2012-05-21 2023-12-13 Insmed Incorporated Systems for treating pulmonary infections
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
EP2682106A1 (en) 2012-07-03 2014-01-08 Phares Pharmaceutical Research N.V. Method of solubilizing biologically active compounds
WO2014034669A1 (ja) * 2012-08-28 2014-03-06 国立大学法人北海道大学 非極性溶媒に分散性を有する細菌菌体成分を内封する脂質膜構造体およびその製造方法
EP2892524B1 (en) 2012-09-04 2020-11-25 Eleison Pharmaceuticals, LLC Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
AU2013352259B2 (en) 2012-11-29 2018-06-14 Insmed Incorporated Stabilized vancomycin formulations
US9895385B2 (en) 2014-05-15 2018-02-20 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
PT3337467T (pt) 2015-08-20 2021-01-25 Ipsen Biopharm Ltd Terapia de combinação utilizando irinotecano lipossomal e um inibidor parp para tratamento do cancro
SG10201913077QA (en) 2015-08-21 2020-02-27 Ipsen Biopharm Ltd Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
BR122021024957B1 (pt) 2015-10-16 2023-12-12 Ipsen Biopharm Ltd Processos de produção de uma composição de irinotecano lipossômico estabilizado em armazenamento
CN106924195B (zh) * 2015-12-31 2020-11-13 南京绿叶制药有限公司 一种注射用紫杉醇脂质体组合物的冻干工艺
CR20180388A (es) * 2016-01-07 2018-09-11 Univ Western Health Sciences Formulaciones para el tratamiento del cáncer de vejiga
WO2018080253A1 (ko) * 2016-10-31 2018-05-03 아이진 주식회사 면역반응 조절물질 및 양이온성 리포좀을 포함하는 면역증강용 조성물 및 이의 용도
AU2017354903B2 (en) 2016-11-02 2023-04-13 Ipsen Biopharm Ltd. Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
JP7460534B2 (ja) 2018-03-30 2024-04-02 インスメッド インコーポレイテッド リポソーム医薬品の連続製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4885172A (en) * 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4766046A (en) * 1985-09-27 1988-08-23 Liposome Technology, Inc. Stabilized liposome/amphotericin composition and method
FR2593394A1 (fr) * 1986-01-30 1987-07-31 Ire Celltarg Sa Procede de preparation de liposomes contenant une subtance active lipophile, notamment de l'amphotericine, liposomes et nouveau medicament obtenus
AU6833994A (en) * 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
GB9320668D0 (en) * 1993-10-07 1993-11-24 Secr Defence Liposomes containing particulare materials
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
DE4432378A1 (de) 1994-09-12 1996-03-14 Bayer Ag Injizierbare liposomale Arzneizubereitungen
EP0792143B1 (en) * 1994-11-18 2002-09-04 Aphios Corporation Methods for making liposomes containing hydrophobic drugs
GB9813100D0 (en) * 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane

Similar Documents

Publication Publication Date Title
JP2003521508A5 (ja)
EP1259225B1 (en) Process of dehydration/rehydration for making liposomes
Hao et al. Studies on a high encapsulation of colchicine by a niosome system
Panos et al. New drug delivery systems based on chitosan
Leo et al. In vitro evaluation of PLA nanoparticles containing a lipophilic drug in water-soluble or insoluble form
CA2723563C (en) Method of forming non-immunogenic hydrophobic protein nanoparticles, and uses therefor
Shi et al. Stealth PEG-PHDCA niosomes: effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity
RU2216315C2 (ru) Способ получения липосом
KR101870316B1 (ko) 음이온성 약물을 함유하는 고분자 미셀의 제조방법
Poyner et al. A comparative study on the pulmonary delivery of tobramycin encapsulated into liposomes and PLA microspheres following intravenous and endotracheal delivery
JP3267611B2 (ja) リポソーム−ポリエンプレリポソーム粉末とその製造方法
Gupta et al. Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting
WO1987001933A1 (en) Stabilized liposome/amphotericin composition and method
EP0771566A1 (en) Stabilization of colloidal systems by the formation of ionic lipid-polysaccharide complexes
WO2004035032A2 (en) Pharmaceutical formulations of camptothecine derivatives
JP2010505785A5 (ja)
US20170202774A1 (en) Liposome composition and method for producing same
Meyer et al. Efficient encapsulation of proteins within liposomes for slow release in vivo
US6468558B2 (en) Liposome-encapsulated poly ICLC
ES2279172T3 (es) Nanoparticulas para la administracion de ingredientes activos, procedimiento para la elaboracion de dichas particulas y composiciones que las contienen.
CA2447990A1 (en) Encapsulation of nanosuspensions in liposomes and microspheres
EP2792350B1 (en) Nanoparticulate systems prepared from sorbitan esters
US20060030578A1 (en) Pharmaceutically active lipid based formulation of irinotecan
CN108102082B (zh) 聚己内酯基二乙基磺丙基甜菜碱及制备方法以及其作为药物释放载体的构建方法
CN105125493B (zh) 一种雷公藤甲素纳米脂质体的制备方法